Hi Stan,

My lymph node results came back today. Seems l have a cocktail of deviant B-Cells. I am curious if Rituxan will only treat a subset of those. I will ask my doc.
CD5+ lambda-restricted B cells (about 18%)
- CD5+ kappa-restricted B cells (about 14%)
- Kappa-restricted B cells negative for CD5 and CD10 (about 36%)
- Kappa-restricted B-lineage cells/plasma cells (about 1%)

My WBC this time was >36K, RBC and platelets are on the low side.

How did your Rituxan treatments go? Were you able to function normally between them, or did you need to take time off (if you work)?

My doc mentioned that follow up treatments post-Rituxan could involve other therapies. I did find this article on the web, in case you are interested. Here is a relevant excerpt. Has your doc discussed any alternatives? It sounds like you are still in a sit & wait period.

"The current therapeutic scenario is predicted to rapidly change as emerging novel agents, especially Bruton's tyrosine kinase inhibitors, have demonstrated promising efficacy and safety profiles, leading to their approval in the relapsed setting.

Moreover, a large variety of novel agents (phosphatidylinositol 3-kinase inhibitors, chimeric antigen receptor T-cells, bispecific antibodies) are being tested in MZL patients with encouraging preliminary results. https://pubmed.ncbi.nlm.nih.gov/36485086/ "

Yes, UMN is U of MN.